A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569
This study is recruiting at 12 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer
- PDAC - Pancreatic Ductal Adenocarcinoma
- NSCLC (Non-small Cell Lung Cancer)
- CRC (Colorectal Cancer)
- Advanced Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alterome Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- June 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Research Site · Orlando, FL
Massachusetts · 2
- Research Site · Boston, MA
- Research Site · Boston, MA
Missouri · 1
- Research Site · St Louis, MO
New York · 2
- Research Site · New York, NY
- Research Site · New York, NY
North Carolina · 1
- Research Site · Durham, NC
Tennessee · 1
- Research Site · Nashville, TN
Texas · 3
- Research Site · Houston, TX
- Research Site · San Antonio, TX
- Research Site #2 · San Antonio, TX
Virginia · 1
- Research Site · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.